Thin EBUS Pilot Study

Clinical Evaluation of the Thin TCP-EBUS Bronchoscopy System

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04745962

Enrollment

Registered

2021-02-09

Start date

2020-09-09

Completion date

2024-09-28

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung; Node

Brief summary

This is a single-center pilot study at the Medical University of South Carolina (MUSC) to evaluate the safety and efficacy of the TCP-EBUS scope (Thin EBUS). This study will consist of a standard of care bronchoscopy and will be followed for approximately 3 months. While the device is not FDA approved, it is the same technology but a thinner version of the SCP-EBUS bronchoscope.

Interventions

DEVICESlimscope

Slimscope thin EBUS endoscope is inserted and used to visualize lung nodules.

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Willing and able to provide informed consent. 2. \>21 years of age or older. 3. Target lesion(s) within the middle third of the lung, which will be determined radiographically prior to scheduling the procedure by the bronchoscopist or radiologist, or by being located at least 2 airway generations from the main carina as seen radiographically. 4. Target lesion(s) location documented on CT scan report. 5. Indicated for bronchosocpy. 6. Bronchoscopic procedure scheduled within 30 days of the CT scan report.

Exclusion criteria

1. Not suitable for flexible bronchoscopy as determined by the treating physician prior to the procedure. 2. Currently on anticoagulation medications with INR \>1.5. 3. Currently using DOAC and does not suspend use at least 7 days prior to the index procedure 4. Currently using Plavix and does not suspend use for at least 7 days prior to the index procedure.

Design outcomes

Primary

Measure	Time frame	Description
Ability to visualize lung nodule	Throughout the procedure (approximately 1 hour)	Study team will determine whether or not the lung nodule was able to be visualized by the scope.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORNicholas J Pastis, MD

The Medical University of South Carolina

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026